<?xml version="1.0" encoding="UTF-8" ?>
<rss version="2.0">
    <channel>
        <title>RSS Feed</title>
        <description>Welcome to our RSS Feed</description>
        <copyright> 2026</copyright>
        <link>
        https://www.msbase.org/news/rss/
        </link>
        <lastBuildDate>Thu, 02 April 2026 00:00:00</lastBuildDate>
        <pubDate>Thu, 02 April 2026 00:00:00</pubDate>

            <item>
                <title>Impact of Age at Onset on Relapse and Disability in AQP4-IgG Neuromyelitis Optica Spectrum Disorder</title>
                <description><![CDATA[ <a href="https://www.msbase.org/news/impact-of-age-at-onset-on-relapse-and-disability-in-aqp4-igg-neuromyelitis-optica-spectrum-disorder/">Continue reading</a>]]></description>
                <link>
                https://www.msbase.org/news/impact-of-age-at-onset-on-relapse-and-disability-in-aqp4-igg-neuromyelitis-optica-spectrum-disorder/
                </link>
                <pubDate>Thu, 02 April 2026 00:00:00</pubDate>
            </item>
            <item>
                <title>Managing reactivation of multiple sclerosis during treatment with natalizumab</title>
                <description><![CDATA[ <a href="https://www.msbase.org/news/managing-reactivation-of-multiple-sclerosis-during-treatment-with-natalizumab/">Continue reading</a>]]></description>
                <link>
                https://www.msbase.org/news/managing-reactivation-of-multiple-sclerosis-during-treatment-with-natalizumab/
                </link>
                <pubDate>Wed, 18 March 2026 00:00:00</pubDate>
            </item>
            <item>
                <title>Real-world effectiveness of horizontal switching between disease-modifying therapies in multiple sclerosis: a retrospective analysis of the MSBase Registry</title>
                <description><![CDATA[ <a href="https://www.msbase.org/news/real-world-effectiveness-of-horizontal-switching-between-disease-modifying-therapies-in-multiple-sclerosis-a-retrospective-analysis-of-the-msbase-registry/">Continue reading</a>]]></description>
                <link>
                https://www.msbase.org/news/real-world-effectiveness-of-horizontal-switching-between-disease-modifying-therapies-in-multiple-sclerosis-a-retrospective-analysis-of-the-msbase-registry/
                </link>
                <pubDate>Wed, 11 March 2026 10:10:00</pubDate>
            </item>
            <item>
                <title>Moderate&#x2013;high efficacy disease-modifying therapies reduce relapse risk in late-onset multiple sclerosis</title>
                <description><![CDATA[ <a href="https://www.msbase.org/news/moderate-high-efficacy-disease-modifying-therapies-reduce-relapse-risk-in-late-onset-multiple-sclerosis/">Continue reading</a>]]></description>
                <link>
                https://www.msbase.org/news/moderate-high-efficacy-disease-modifying-therapies-reduce-relapse-risk-in-late-onset-multiple-sclerosis/
                </link>
                <pubDate>Wed, 11 March 2026 00:00:00</pubDate>
            </item>
            <item>
                <title>Disease-modifying treatment and disability progression in subclasses of patients with primary progressive MS: results from the Big MS Data Network</title>
                <description><![CDATA[ <a href="https://www.msbase.org/news/disease-modifying-treatment-and-disability-progression-in-subclasses-of-patients-with-primary-progressive-ms-results-from-the-big-ms-data-network/">Continue reading</a>]]></description>
                <link>
                https://www.msbase.org/news/disease-modifying-treatment-and-disability-progression-in-subclasses-of-patients-with-primary-progressive-ms-results-from-the-big-ms-data-network/
                </link>
                <pubDate>Wed, 14 May 2025 00:00:00</pubDate>
            </item>
            <item>
                <title>Standardized Definition of Progression Independent of Relapse Activity (PIRA) in Relapsing-Remitting Multiple Sclerosis</title>
                <description><![CDATA[ <a href="https://www.msbase.org/news/standardized-definition-of-progression-independent-of-relapse-activity-pira-in-relapsing-remitting-multiple-sclerosis/">Continue reading</a>]]></description>
                <link>
                https://www.msbase.org/news/standardized-definition-of-progression-independent-of-relapse-activity-pira-in-relapsing-remitting-multiple-sclerosis/
                </link>
                <pubDate>Mon, 14 April 2025 00:00:00</pubDate>
            </item>
            <item>
                <title>Utility of icobrain for brain volumetry in multiple sclerosis clinical practice</title>
                <description><![CDATA[ <a href="https://www.msbase.org/news/utility-of-icobrain-for-brain-volumetry-in-multiple-sclerosis-clinical-practice/">Continue reading</a>]]></description>
                <link>
                https://www.msbase.org/news/utility-of-icobrain-for-brain-volumetry-in-multiple-sclerosis-clinical-practice/
                </link>
                <pubDate>Mon, 02 December 2024 00:00:00</pubDate>
            </item>
            <item>
                <title>Prevalence of Progression Independent of Relapse Activity and Relapse-Associated Worsening in Patients With AQP4-IgG-Positive NMOSD</title>
                <description><![CDATA[ <a href="https://www.msbase.org/news/prevalence-of-progression-independent-of-relapse-activity-and-relapse-associated-worsening-in-patients-with-aqp4-igg-positive-nmosd/">Continue reading</a>]]></description>
                <link>
                https://www.msbase.org/news/prevalence-of-progression-independent-of-relapse-activity-and-relapse-associated-worsening-in-patients-with-aqp4-igg-positive-nmosd/
                </link>
                <pubDate>Tue, 19 November 2024 00:00:00</pubDate>
            </item>
            <item>
                <title>Disease Activity in Pregnant and Postpartum Women With Multiple Sclerosis Receiving Ocrelizumab or Other Disease-Modifying Therapies</title>
                <description><![CDATA[ <a href="https://www.msbase.org/news/disease-activity-in-pregnant-and-postpartum-women-with-multiple-sclerosis-receiving-ocrelizumab-or-other-disease-modifying-therapies/">Continue reading</a>]]></description>
                <link>
                https://www.msbase.org/news/disease-activity-in-pregnant-and-postpartum-women-with-multiple-sclerosis-receiving-ocrelizumab-or-other-disease-modifying-therapies/
                </link>
                <pubDate>Mon, 11 November 2024 00:00:00</pubDate>
            </item>
    </channel>
</rss>




